$JBL

UBS upgrades Jabil to buy on AI growth, raises estimates; keeps $430 target

UBS upgraded Jabil (JBL) to Buy from Neutral, citing stronger AI-driven demand and a more diversified business mix. UBS kept a $430 price target and raised fiscal 2027 and 2028 EPS estimates to $16.78 and $20.24. It expects AI revenue to grow at least 50% in FY2027 to about $20.3B, supported by hyperscalers including Amazon, Meta and Google.

Original reporting
Published Aug 11, 2026, 3:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 4:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$JBL
Bullish
medium confidence
Mentioned
$JBL
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$JBLBullishMed
01

Why it matters

The key tradable change is the analyst upgrade plus raised EPS and revenue estimates, supported by quantified AI revenue growth expectations and hyperscaler contribution assumptions.

02

Market read

This is a company-specific sell-side catalyst with explicit estimate revisions and a maintained price target, likely influencing short-term sentiment and positioning.

03

What to watch

Valuation multiple reduction (to about 22x from 25x) and higher capital costs could limit upside even with higher estimates, especially if AI infrastructure de-rating continues.

Relevance 7/10Novelty 6/10Timing: today, pre-market/afternoon analyst note driving positioning ahead of next inflation catalyst

Background

UBS frames Jabil as benefiting from AI-driven demand, diversified business mix, and margin improvement from automation/robotics and facility ramps.

Company-level read

Ticker impact

$JBLBullishMedium confidence
Context

UBS upgraded Jabil to Buy from Neutral, kept a $430 target, and raised fiscal 2027-2028 EPS estimates on AI-driven demand.

Expected impact

Likely supportive for the stock over the next days to weeks, especially if investors treat the PT and AI demand assumptions as credible read-through.

Evidence & confidence

The article provides specific analyst actions (rating change, PT, and EPS/revenue estimate increases) plus concrete demand drivers (hyperscaler revenue, capacity expansion, Hanley acquisition, healthcare facility ramp).

Market effects

Reinforces the AI infrastructure supply-chain read-through for electronics manufacturing and data-center related capex beneficiaries.

No specific regional macro or policy linkage beyond facility capacity expansion in Memphis and North Carolina.

Hyperscaler demand assumptions (Amazon, Meta, Google) tie the thesis to global cloud capex cycles.

Counterpoint

The note relies on supply-chain checks and hyperscaler incremental revenue assumptions that may prove timing-sensitive versus actual customer capex pacing.

Key entities

  • Jabil

    Subject of the UBS upgrade, with raised fiscal 2027-2028 EPS and maintained $430 price target.

  • UBS

    Issued the Buy rating and estimate changes cited in the article.

  • Amazon

    Expected to contribute roughly $1 billion in incremental revenue to Jabil in the UBS model.

  • Meta

    Expected to contribute roughly $1 billion in incremental revenue to Jabil in the UBS model.

  • Google

    UBS expects a third hyperscaler, believed to be Google, to provide another growth tailwind later in fiscal 2027.

Related articles

$AKAMHighAI 9/10

Anthropic signs US$11.6 billion cloud deal with Akamai, gets warrant for up to 5% stake

Anthropic agreed to a US$11.6 billion cloud services deal with Akamai, including a warrant for up to 5% stake. Akamai shares rose 20% in extended trading. The 7-year contract involves purchasing Series B shares at US$111.33 each, converting to 7.7 million common shares. Akamai expects US$5.5 billion in capital expenditure and US$1.7 billion increase in 2026 spending.

$JBLMed

Why Jabil (JBL) Shares Are Plunging Today

Jabil (JBL) shares fell 5.1% after Goldman Sachs lowered its price target to $375, citing a more cautious valuation. The stock is volatile, down 22% from its 52-week high, but up 25.1% year-to-date. Higher bond yields and oil prices pose risks for the company.

$JBLMed

JBL Stock Rises as Goldman Sachs Backs AI Growth Story

Jabil Inc. (JBL) stock rose 5.65% after strong earnings guidance. Goldman Sachs, while cutting its target to $375, expects 50% AI revenue growth and 6% EBIT margins. JBL reported $8.75B revenue, $275M net income, and 3% profit margin. The stock is in an uptrend, with support at $300 and resistance around $340.

$JBLMedAI 8/10

Jabil Rises 36.2% Year to Date: Should You Buy the Stock?

Jabil Inc. (JBL) has risen 36.2% year-to-date, outperforming its industry and the S&P 500. The company expects AI-related revenues to reach $13.6B in fiscal 2026, up from $9B in 2025, and is expanding manufacturing capacity to meet demand. JBL also sees growth in healthcare, renewable energy, and digital commerce sectors, but faces supply chain and competition challenges.

$JBLHighAI 8/10

FDA Contamination Warning Could Be A Game Changer For Jabil’s (JBL) Pharma Ambitions

The FDA issued a warning to Jabil's Pharmaceutics International facility, citing significant violations of sterile drug manufacturing practices, including fungal contamination and weak quality oversight. This raises concerns about Jabil's ability to manufacture sterile products and could impact its pharmaceutical expansion plans. Jabil's 2026 revenue guidance of $35 billion includes contributions from healthcare and pharma, which may now be questioned by investors.

$JBLHighAI 8/10

Jabil Stock: Is Wall Street Bullish or Bearish?

Jabil Inc. (JBL), a $33.8B electronic manufacturing services provider, reported Q3 2026 adjusted EPS of $3.16 and revenue of $8.75B, exceeding expectations. The company raised its fiscal 2026 guidance, citing strong AI data-center demand and new partnerships. Shares have surged 58.6% over 52 weeks, outperforming the S&P 500. Analysts rate it a 'Strong Buy' with a mean price target of $451.18.